$LLY has a much higher valuation than $NOVO B. What speaks in favor of $LLY is that they would not be affected by the tariffs and they currently have the perhaps slightly better obesity medication. $NOVO B would be affected by tariffs, but they also make a lot of money with diabetes medication. The Americans can't do without that either. I just don't believe that $LLY is so much better that it justifies such a difference in valuation.
Novo Nordisk currently looks somewhat more attractive in direct comparison with Eli Lilly - especially from a fundamental perspective. The company has a strong market position in the GLP-1 segment, solid profitability and a relatively moderate valuation. Novo is more robust, particularly in terms of its price/earnings ratio and margin structure.
The management is also very disciplined in its operations: The supply chains are stable, production is highly integrated and the pipeline is broadly positioned - especially in the obesity and diabetes area. While Eli Lilly relies heavily on momentum, Novo has more fundamental stability and a long-term strategy.
The bottom line is that Novo Nordisk is not the more spectacular choice, but in many respects it is the more solid and currently somewhat cheaper one.
Since I am Danish, I would say: the share is simply too cheap😂 ne fun I am also convinced of the company but here in this country everyone loves this company, which is why I think that also had an influence on my decision😂
Because there is already a bit of a bubble here Which doesn't necessarily mean anything with regard to the stock mentioned, but you should keep that in mind a bit